Zhang Junshi, Liu Tingting, Wu Haojie, Wei Jianshe, Qu Qiumin
Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Neurology, Huaihe Hospital of Henan University, Kaifeng, China.
J Alzheimers Dis. 2025 May 7:13872877251339771. doi: 10.1177/13872877251339771.
BackgroundAlzheimer's disease (AD) is characterized by amyloid-β deposits, neurofibrillary tangles, and hippocampal neurodegeneration, with oxidative stress and mitochondrial dysfunction playing critical roles in its pathogenesis. Identifying hub genes associated with these processes could advance biomarker discovery and therapeutic strategies.ObjectiveThis study aimed to identify key oxidative stress- and mitochondrial dysfunction-related genes in the AD hippocampus, evaluate their diagnostic potential, and explore therapeutic agents targeting these genes.MethodsWe analyzed datasets GSE48350 and GSE5281, encompassing 56 controls and 29 AD patients. Weighted gene co-expression network analysis (WGCNA) selected genes with significance (adjusted -value < 0.05 and |logFC| ≥ 0.5). Further studies involved immune cell infiltration, Gene set enrichment analysis (GSEA), and intersecting differentially expressed genes (DEGs) with oxidative stress-related genes (ORGs) and mitochondrial dysfunction-related genes (MDRGs). Functional enrichment and Protein-protein interaction (PPI) analyses were conducted. Experimental validation was done in AD mouse models, and diagnostic potential was tested using datasets GSE28146 and GSE29652. Therapeutic drugs were predicted based on hub genes.ResultsAD showed altered immune cell expression. GSEA linked DEGs to nervous system processes and neurotransmitters. 194 oxidative stress-related DEGs were enriched in neuronal death and mitochondrial processes. PPI analysis identified 24 DEGs related to both oxidative stress and mitochondrial dysfunction (DEO-MDRGs), with diagnostic potential (AUC > 0.5). LASSO regression selected four DEO-MDRGs: NDUFV2, NDUFS7, OPA1, and NDUFA1. Their protein levels were reduced in AD mice with decreased mitochondrial function. These genes showed good diagnostic performance. Potential drugs, like ME-344 and metformin hydrochloride, may be useful in AD treatment.ConclusionsNDUFV2, NDUFS7, OPA1, and NDUFA1 can serve as biomarkers for AD diagnosis.
背景
阿尔茨海默病(AD)的特征是淀粉样β沉积、神经原纤维缠结和海马神经退行性变,氧化应激和线粒体功能障碍在其发病机制中起关键作用。识别与这些过程相关的枢纽基因可能会推动生物标志物的发现和治疗策略的发展。
目的
本研究旨在识别AD海马中与氧化应激和线粒体功能障碍相关的关键基因,评估它们的诊断潜力,并探索靶向这些基因的治疗药物。
方法
我们分析了数据集GSE48350和GSE5281,其中包括56名对照和29名AD患者。加权基因共表达网络分析(WGCNA)选择具有显著性的基因(调整后p值<0.05且|logFC|≥0.5)。进一步的研究包括免疫细胞浸润、基因集富集分析(GSEA),以及将差异表达基因(DEGs)与氧化应激相关基因(ORGs)和线粒体功能障碍相关基因(MDRGs)进行交叉分析。进行了功能富集和蛋白质-蛋白质相互作用(PPI)分析。在AD小鼠模型中进行了实验验证,并使用数据集GSE28146和GSE29652测试了诊断潜力。基于枢纽基因预测了治疗药物。
结果
AD显示免疫细胞表达改变。GSEA将DEGs与神经系统过程和神经递质联系起来。194个与氧化应激相关的DEGs在神经元死亡和线粒体过程中富集。PPI分析确定了24个与氧化应激和线粒体功能障碍都相关的DEGs(DEO-MDRGs),具有诊断潜力(AUC>0.5)。LASSO回归选择了四个DEO-MDRGs:NDUFV2、NDUFS7、OPA1和NDUFA1。它们在AD小鼠中的蛋白质水平降低,线粒体功能下降。这些基因显示出良好的诊断性能。潜在药物,如ME-344和盐酸二甲双胍,可能对AD治疗有用。
结论
NDUFV2、NDUFS7、OPA1和NDUFA1可作为AD诊断的生物标志物。